Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shouvik Dass

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Expert Opinion on Pharmacotherapy|December 8, 2006
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritisShouvik Dass, Edward M Vital, Paul Emery
Arthritis and Rheumatism|August 1, 2007
Development of psoriasis after B cell depletion with rituximabShouvik Dass, Edward M Vital, Paul Emery
Annals of the Rheumatic Diseases|January 21, 2014
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trialEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Arthritis and Rheumatism|September 30, 2008
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisShouvik Dass, Andy C Rawstron, Edward M Vital, et al.
Frontiers in Medicine|September 28, 2020
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than BelimumabSabih Ul Hassan, Md Yuzaiful Md Yusof, Paul Emery, et al.
Rheumatology Advances in Practice|August 8, 2022
Single-centre experience of refractory rheumatoid arthritisJohn Fitton, Andrew Melville, Kamran Naraghi, et al.
Arthritis and Rheumatism|March 2, 2011
Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletionEdward M Vital, Andrew C Rawstron, Shouvik Dass, et al.
Rheumatology (Oxford, England)|October 1, 2025
Predicting rapid radiographic progression in difficult-to-treat rheumatoid arthritis: insights from long-term follow-upKerem Abacar, Andrea Di Matteo, Paula David, et al.
Rheumatology (Oxford, England)|April 27, 2017
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centreMd Yuzaiful Md Yusof, Angela Kabia, Michael Darby, et al.
The Lancet. Rheumatology|January 30, 2023
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort studyMd Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|December 8, 2006
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritisShouvik Dass, Edward M Vital, Paul Emery
Arthritis and Rheumatism|August 1, 2007
Development of psoriasis after B cell depletion with rituximabShouvik Dass, Edward M Vital, Paul Emery
Annals of the Rheumatic Diseases|January 21, 2014
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trialEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Arthritis and Rheumatism|September 30, 2008
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisShouvik Dass, Andy C Rawstron, Edward M Vital, et al.
Frontiers in Medicine|September 28, 2020
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than BelimumabSabih Ul Hassan, Md Yuzaiful Md Yusof, Paul Emery, et al.
Rheumatology Advances in Practice|August 8, 2022
Single-centre experience of refractory rheumatoid arthritisJohn Fitton, Andrew Melville, Kamran Naraghi, et al.
Arthritis and Rheumatism|March 2, 2011
Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletionEdward M Vital, Andrew C Rawstron, Shouvik Dass, et al.
Rheumatology (Oxford, England)|October 1, 2025
Predicting rapid radiographic progression in difficult-to-treat rheumatoid arthritis: insights from long-term follow-upKerem Abacar, Andrea Di Matteo, Paula David, et al.
Rheumatology (Oxford, England)|April 27, 2017
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centreMd Yuzaiful Md Yusof, Angela Kabia, Michael Darby, et al.
The Lancet. Rheumatology|January 30, 2023
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort studyMd Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, et al.
Pageof 3